Recent progress in nanotechnology-based novel drug delivery systems in designing of cisplatin for cancer therapy: an overview

Cisplatin cis-(diammine)dichloridoplatinum(II) (CDDP) is the first platinum-based complex approved by the food and drug administration (FDA) of the United States (US). Cisplatin is the first line chemotherapeutic agent used alone or combined with radiations or other anti-cancer agents for a broad ra...

Full description

Saved in:
Bibliographic Details
Published in:Artificial cells, nanomedicine, and biotechnology nanomedicine, and biotechnology, 2019-12, Vol.47 (1), p.1674-1692
Main Authors: Farooq, Muhammad Asim, Aquib, Md, Farooq, Anum, Haleem Khan, Daulat, Joelle Maviah, Mily Bazezy, Sied Filli, Mensura, Kesse, Samuel, Boakye-Yiadom, Kofi Oti, Mavlyanova, Rukhshona, Parveen, Amna, Wang, Bo
Format: Article
Language:English
Subjects:
Anticancer properties
cancer
Cancer therapies
Cisplatin
Clinical trials
Drug delivery
drug delivery system
Drug delivery systems
Drug resistance
inorganic carriers
Nanotechnology
Platinum
polymeric nanoparticles
Regulatory agencies
Trademarks
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cisplatin cis-(diammine)dichloridoplatinum(II) (CDDP) is the first platinum-based complex approved by the food and drug administration (FDA) of the United States (US). Cisplatin is the first line chemotherapeutic agent used alone or combined with radiations or other anti-cancer agents for a broad range of cancers such as lung, head and neck. Aroplatin™, Lipoplatin™ and SPI-077 are PEGylated liposome-based nano-formulations that are still under clinical trials. They have many limitations, for example, poor aqueous solubility, drug resistance and toxicities, which can be overcome by encapsulating the cisplatin in Nemours nanocarriers. The extensive literature from different electronic databases covers the different nano-delivery systems that are developed for cisplatin. This review critically emphasizes on the recent advancement, development, innovations and updated literature reported for different carrier systems for CDDP.
ISSN:2169-1401
2169-141X
DOI:10.1080/21691401.2019.1604535